ARS Pharmaceuticals Inc
For the period ended Jun 30, 2024. Filed Aug 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 6, 2024
SPRY$3.57+13.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share data)
| Common Stock | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Additional Paid-in Capital | Accumulated Other Comprehensive (Loss) Gain, Net | Accumulated Deficit | Total Stockholders’ Equity | |
| Balance at December 31, 2023 | 96,414,963 | $10 | $362,004 | $49 | $(131,303) | $230,760 |
| Exercise of common stock options and release of restricted stock units | 159,086 | — | 258 | — | — | 258 |
| Stock-based compensation | — | — | 3,315 | — | — | 3,315 |
| Net loss and comprehensive loss | — | — | — | (173) | (10,292) | (10,465) |
| Balance at March 31, 2024 | 96,574,049 | $10 | $365,577 | $(124) | $(141,595) | $223,868 |
| Exercise of common stock options, shares issued under the employee stock purchase plan, and release of restricted stock units | 365,748 | — | 545 | — | — | 545 |
| Stock-based compensation | — | — | 3,365 | — | — | 3,365 |
| Net loss and comprehensive loss | — | — | — | (21) | (12,516) | (12,537) |
| Balance at June 30, 2024 | 96,939,797 | $10 | $369,487 | $(145) | $(154,111) | $215,241 |
| Common Stock | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Additional Paid-in Capital | Accumulated Other Comprehensive Gain (Loss), Net | Accumulated Deficit | Total Stockholders’ Equity | |
| Balance at December 31, 2022 | 93,943,316 | $9 | $349,408 | $407 | $(76,938) | $272,886 |
| Exercise of common stock options and release of restricted stock units | 504,712 | — | 1,319 | — | — | 1,319 |
| Stock-based compensation | — | — | 2,250 | — | — | 2,250 |
| Net loss and comprehensive loss | — | — | — | (339) | (14,961) | (15,300) |
| Balance at March 31, 2023 | 94,448,028 | $9 | $352,977 | $68 | $(91,899) | $261,155 |
| Exercise of common stock options, shares issued under the employee stock purchase plan, and release of restricted stock units | 874,925 | — | 2,854 | — | — | 2,854 |
| Stock-based compensation | — | — | 2,161 | — | — | 2,161 |
| Net loss and comprehensive loss | — | — | — | (248) | (17,370) | (17,618) |
| Balance at June 30, 2023 | 95,322,953 | $9 | $357,992 | $(180) | $(109,269) | $248,552 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.